Joseph Klebba

Company: Vividion Therapeutics

Job title: Associate Director

Seminars:

Targeting the RAS-PI3Kα Interaction as an Efficacious & Tolerated Means of Inhibiting the PI3K/AKT Pathway in RAS-Diven Cancers 4:15 pm

• Identification and functionalization of C242, unique to p110α, to disrupt RAS-driven activation of PI3Kα • Pre-clinical models identify disruption of the RAS-PI3Kα interaction as an efficacious and well tolerated means of targeting the PI3K/AKT pathway • Detailed mechanistic exploration identifies the PI3K/AKT pathway as critical signaling node that drives resistance to direct targeting of…Read more

day: Day Two